Canadian biotech company Qvella, headquartered in Toronto, is a molecular diagnostics company with new detection technology – preparing to bring a solution to the question of whether, and what, to prescribe when treating a possible infection is a problem.
If antibiotics are needed, they are most effective if used promptly – but the price of giving unnecessary treatment can be high, and includes not only the cost of the drugs themselves but also the growth of resistant strains of bacteria.
Currently, doctors can only get a definitive answer as to whether a patient is infected, and with what type of bacteria, after a sample from the patient is cultured in a lab, a process that takes between 24 and 72 hours. When a patient is in crisis, waiting that long simply isn’t an option. Sepsis, sometimes called a blood infection, is one such serious condition. It is the second cause of death among critical patients.
-original.png){kind=spacer}
oxfaz.wordpress.com 